Liu Jie, Xu Mengyuan, Zhang Xiaoqian, Zhang Zhuo, Zhong Tao, Yu Hongjuan, Fu Yueyue, Meng Hongbin, Feng Jiawei, Zou Xindi, Han Xueying, Kang Liqing, Yu Lei, Li Limin
Department of Hematology, The First Affiliated Hospital, Harbin Medical University, The Institute of the Hematology and Oncology of Heilongjiang Province, Harbin, Heilongjiang, PR China.
Department of Hematology, South University of Science and Technology Hospital, Shenzhen, Guangdong, PR China.
Heliyon. 2024 Jul 1;10(13):e33937. doi: 10.1016/j.heliyon.2024.e33937. eCollection 2024 Jul 15.
Chimeric antigen receptor (CAR)-T cell therapy has been confirmed improving remission rates in refractory patients or relapsed B-cell acute lymphoblastic leukemia (R/R B-ALL). However, the added benefits of undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) following CAR-T therapy remain a subject of debate. In this research we investigated the efficiency and long-term outcomes of CD19 CAR-T bridging with allo-HSCT in R/R B-ALL patients. A total of 42 patients were brought into the cohort studies. Our findings revealed that patients who appected CAR-T followed by HSCT had a 1-year overall survival (OS) rate of 70 % and a 1-year leukemia-free survival (LFS) rate of 95 %. Moreover, patients who underwent this combined treatment had higher OS and LFS rates compared to those who received CAR-T therapy alone. In conclusion, the results of this clinical trial provide compelling evidence for the safety and efficacy of using CAR-T therapy as a bridging strategy to allo-HSCT in patients with R/R B-ALL.
嵌合抗原受体（CAR）-T细胞疗法已被证实可提高难治性或复发性B细胞急性淋巴细胞白血病（R/R B-ALL）患者的缓解率。然而，CAR-T治疗后接受异基因造血干细胞移植（allo-HSCT）的额外益处仍存在争议。在本研究中，我们调查了R/R B-ALL患者中CD19 CAR-T桥接allo-HSCT的疗效和长期预后。共有42例患者纳入队列研究。我们的研究结果显示，接受CAR-T治疗后再进行HSCT的患者1年总生存率（OS）为70%，1年无白血病生存率（LFS）为95%。此外，与仅接受CAR-T治疗的患者相比，接受这种联合治疗的患者的OS和LFS率更高。总之，该临床试验结果为在R/R B-ALL患者中使用CAR-T疗法作为allo-HSCT的桥接策略的安全性和有效性提供了有力证据。
